Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia
This study is completed in France, in the United Kingdom, in Croatia, .... It is testing Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia.
SchizophreniaDrugFrom 18 Years to 50 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Transition may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Transition, attend study visits with the research team. The registry lists locations in Croatia, in Denmark, and in France.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: April 28, 2016
Recruitment status
Completed
Enrollment listed in the registry
306
Sponsor
Janssen-Cilag Ltd.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France, United Kingdom, Croatia, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT02713282
Official title
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Croatia · 2 sites
Rijeka
Rijeka
Site status: Not listed — confirm with the team
Zagreb
Zagreb
Site status: Not listed — confirm with the team
Denmark · 1 site
Esbjerg
Esbjerg
Site status: Not listed — confirm with the team
France · 5 sites
Clermont-Ferrand
Clermont-Ferrand
Site status: Not listed — confirm with the team
Montpellier
Montpellier
Site status: Not listed — confirm with the team
Paris
Paris
Site status: Not listed — confirm with the team
Rennes
Rennes
Site status: Not listed — confirm with the team
Toulon
Toulon
Site status: Not listed — confirm with the team
Germany · 4 sites
Berlin
Berlin
Site status: Not listed — confirm with the team
Hamburg
Hamburg
Site status: Not listed — confirm with the team
Oranienburg
Oranienburg
Site status: Not listed — confirm with the team
Stralsund
Stralsund
Site status: Not listed — confirm with the team
Greece · 4 sites
Athens
Athens
Site status: Not listed — confirm with the team
Heraklion
Heraklion
Site status: Not listed — confirm with the team
Nea Kifissia
Nea Kifissia
Site status: Not listed — confirm with the team
Thessaloniki
Thessaloniki
Site status: Not listed — confirm with the team
Israel · 2 sites
Beer Yaakov
Beer Yaakov
Site status: Not listed — confirm with the team
Ramat Gan
Ramat Gan
Site status: Not listed — confirm with the team
Malaysia · 3 sites
Ipoh
Ipoh
Site status: Not listed — confirm with the team
Johor Bahru
Johor Bahru
Site status: Not listed — confirm with the team
Kuala Lumpur
Kuala Lumpur
Site status: Not listed — confirm with the team
Netherlands · 2 sites
Assen
Assen
Site status: Not listed — confirm with the team
Groningen
Groningen
Site status: Not listed — confirm with the team
Russia · 2 sites
Moscow
Moscow
Site status: Not listed — confirm with the team
Saint Petersburg
Saint Petersburg
Site status: Not listed — confirm with the team
Saudi Arabia · 1 site
Jeddah
Jeddah
Site status: Not listed — confirm with the team
South Korea · 4 sites
Gwangju
Gwangju
Site status: Not listed — confirm with the team
Gyeonggi-do
Gyeonggi-do
Site status: Not listed — confirm with the team
Jeonju
Jeonju
Site status: Not listed — confirm with the team
Seoul
Seoul
Site status: Not listed — confirm with the team
Spain · 6 sites
Bilbao
Bilbao
Site status: Not listed — confirm with the team
Madrid
Madrid
Site status: Not listed — confirm with the team
Oviedo
Oviedo
Site status: Not listed — confirm with the team
Sabadell
Sabadell
Site status: Not listed — confirm with the team
Torrevieja
Torrevieja
Site status: Not listed — confirm with the team
Valencia
Valencia
Site status: Not listed — confirm with the team
Taiwan · 3 sites
New Taipei City
New Taipei City
Site status: Not listed — confirm with the team
Tainan
Tainan
Site status: Not listed — confirm with the team
Taoyuan
Taoyuan
Site status: Not listed — confirm with the team
Türkiye · 4 sites
Ankara
Ankara
Site status: Not listed — confirm with the team
Bursa
Bursa
Site status: Not listed — confirm with the team
Istanbul
Istanbul
Site status: Not listed — confirm with the team
Sakarya
Sakarya
Site status: Not listed — confirm with the team
United Kingdom · 3 sites
Derby
Derby
Site status: Not listed — confirm with the team
Edinburgh
Edinburgh
Site status: Not listed — confirm with the team
Reading
Reading
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT02713282. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Paliperidone palmitate 3 month formulation (PP3M). Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 50 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Cilag Ltd., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
